EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access

Clinical Benefit, Price, and Uptake for Cancer Biosimilars vs Reference Drugs in China

Xingxian Luo, Xin Du, Zhuangqi Li, Jingwen Liu, Xufeng Lv, Haoran Li, Qixiang Guo, Cen Wang, Xuecai Xue, Kaidi Le, Xiaomeng Jiang, Lin Huang und 1 weitere

JAMA Network Open · 2023

DOI: 10.1001/jamanetworkopen.2023.37348 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift JAMA Network Open, 2023. Verfasst von Xingxian Luo und 12 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Tsinghua University, Beijing, China. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance The high cost of biologics used to treat cancer has been an increasing burden in the world. In China, the recent approval of cancer biosimilar drugs to resolve this problem is promising, but evidence of clinical benefits, price, and uptake for these drugs is still lacking.

Objectives

To compare characteristics of pivotal clinical trials in China and other countries for biosimilars of bevacizumab, rituximab, and trastuzumab and investigate the efficacy or effectiveness, safety, and immunogenicity outcomes of cancer biosimilars compared with reference drugs by meta-analysis. Data Sources For this systematic review and meta-analysis, PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov were searched for published studies from database inception to February 1, 2023, using the search topics ( cancers ) AND ( biosimilars ). Study Selection Randomized clinical trials and cohort studies that included patients with cancer were included. Data Extraction and Synthesis Two authors independently extracted the outcome estimates and characteristics for each study. A random-effects meta-analysis was performed to summarize the relative estimates with 95% CIs. This study was performed following the Preferred Reporting Items for Systematic Reviews and Meta-analyses guideline. Main Outcomes and Measures Clinical trial characteristics were collected for biosimilars of bevacizumab, rituximab, and trastuzumab. The relative estimates of efficacy or effectiveness (objective response rate, progression-free survival, and overall survival), safety, and immunogenicity outcomes were analyzed for biosimilars vs reference drugs. The weighted average price and uptake rate were evaluated for biosimilars relative to their reference drugs between 2015 and 2022.

Results

A total of 39 RCTs (involving 18 791 patients) and 10 cohort studies (involving 1998 patients) were included. The biosimilars of bevacizumab (16 RCTs; risk ratio [RR], 0.97; 95% CI, 0.93-1.01; P = .17), rituximab (12 RCTs; RR, 1.03; 95% CI, 0.98-1.08; P = .70), and trastuzumab (9 RCTs: RR, 1.04; 95% CI, 0.97-1.12; P = .29) met equivalence with reference biologics in regard to the objective response rate. The results summarized from cohort studies were consistent with those from RCTs. In 2022, cancer biosimilars were priced at 69% to 90% of the costs for the reference drugs, and their uptake reached 54% to 83% in China. Conclusions and Relevance This systematic review and meta-analysis indicated that cancer biosimilars provided comparable clinical benefits at lower prices compared with reference drugs. These findings suggest the potential feasibility of expediting the transition from reference drugs to biosimilars to benefit more patients with cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biosimilar PharmaceuticalsNeoplasmsHumansRituximabBevacizumabTrastuzumab

Substanzen

Biosimilar PharmaceuticalsRituximabBevacizumabTrastuzumab

Autor:innen und Institutionen

  • School of Pharmaceutical Sciences, Tsinghua University, Beijing, China.
  • Key Laboratory of Innovative Drug Research and Evaluation, National Medical Products Administration, Beijing, China.
  • Tsinghua-Peking Center for Life Sciences, Beijing, China.
  • Center for Drug Evaluation, National Medical Products Administration, Beijing, China.
  • School of Life Sciences, Fudan University, Shanghai, China.
  • Department of Pharmacy, Peking University People's Hospital, Beijing, China.

Zitieren

APA

Luo, X., Du, X., Li, Z., Liu, J., Lv, X., Li, H., Guo, Q., Wang, C., Xue, X., Le, K., Jiang, X., Huang, L., & Yang, Y. (2023). Clinical Benefit, Price, and Uptake for Cancer Biosimilars vs Reference Drugs in China. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2023.37348

Vancouver

Luo X, Du X, Li Z, Liu J, Lv X, Li H, et al. Clinical Benefit, Price, and Uptake for Cancer Biosimilars vs Reference Drugs in China. JAMA Network Open. 2023. doi:10.1001/jamanetworkopen.2023.37348

BibTeX
@article{Luo2023,
  author = {Luo, Xingxian and Du, Xin and Li, Zhuangqi and Liu, Jingwen and Lv, Xufeng and Li, Haoran and Guo, Qixiang and Wang, Cen and Xue, Xuecai and Le, Kaidi and Jiang, Xiaomeng and Huang, Lin and Yang, Yue},
  title = {Clinical Benefit, Price, and Uptake for Cancer Biosimilars vs Reference Drugs in China},
  journal = {JAMA Network Open},
  year = {2023},
  doi = {10.1001/jamanetworkopen.2023.37348}
}
Kostenlos starten →